EQS-News: MeVis publishes figures for the first half of fiscal year 2024/2025

27.05.25 15:45 Uhr

Werte in diesem Artikel
Aktien

24,60 EUR -0,60 EUR -2,38%

EQS-News: MeVis Medical Solutions AG / Key word(s): Half Year Report/Half Year Results
MeVis publishes figures for the first half of fiscal year 2024/2025

27.05.2025 / 15:45 CET/CEST
The issuer is solely responsible for the content of this announcement.

Wer­bung


Bremen, May 27, 2025 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading medical imaging software company, today announced its results for the first half of fiscal year 2024/2025, reporting period October 1, 2024 to March 31, 2025.

In the first half of the year, the Company's revenue amounted to € 8,438 thousand (previous year: € 8,774 thousand). Of this amount, 22% (previous year: 27%) was attributable to the sale of licenses, 34% (previous year: 35%) to maintenance revenues, and 44% (previous year: 38%) to other revenues, which include, among other things, services for and charges passed on to affiliated companies and the parent company. Earnings before interest and taxes (EBIT) fell from € 2,092 thousand to € 1,853 thousand, mainly due to lower sales compared with the previous year, higher other operating income and increased personnel expenses, corresponding to an EBIT margin of 22%.

Income from loans as financial assets amounted to € 550 thousand (previous year: € 258 thousand) and is attributable to interest income from the loan granted to Varex Imaging Deutschland AG. This results in earnings before taxes (EBT) of € 2,468 thousand (previous year: € 2,735 thousand).

Wer­bung

Income taxes of € 64 thousand (previous year: € 74 thousand) were incurred in the first half of the year. Therefore, taking into account the expense from the profit to be transferred to Varex Imaging Deutschland AG in the amount of € 2,404 thousand (previous year: € 2,661 thousand), net income amounted to € 0 thousand (previous year: € 0 thousand). It should be noted that the expense from the transfer of earnings only arises legally at the end of the fiscal year.

At this point in time, we are sticking to our forecast: stable to slightly growing sales in the range of € 17.0 million to € 17.5 million are expected for the 2024/2025 financial year. In addition to stable sales with the customer Hologic, sales in the lung and liver segments are expected to increase slightly. We expect development services to remain stable. We expect earnings before interest and taxes (EBIT) for the financial year 2024/2025 to be between € 3.5 million and € 4.0 million, assuming a stable exchange rate of 1.12 USD/EUR. The forecast stability or slight increase in sales and the disproportionately low increase in personnel costs are the main drivers of the positive EBIT outlook.

The Executive Board will regularly review its expectations over the course of the 2024/2025 financial year on the basis of current business developments.

Wer­bung


Contact:
Kirchhoff, Marcus / CEO


27.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany
Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2146352

 
End of News EQS News Service

2146352  27.05.2025 CET/CEST

Ausgewählte Hebelprodukte auf MeVis Medical Solutions

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf MeVis Medical Solutions

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu MeVis Medical Solutions AG

Wer­bung

Analysen zu MeVis Medical Solutions AG

DatumRatingAnalyst
01.09.2010MeVis Medical Solutions kaufenSES Research/ Warburg Gruppe
19.05.2010MeVis kaufenSES Research/ Warburg Gruppe
09.11.2009MeVis kaufenSES Research GmbH
16.09.2009MeVis kaufenSES Research GmbH
08.09.2009MeVis kaufenPerformaxx Research GmbH
DatumRatingAnalyst
01.09.2010MeVis Medical Solutions kaufenSES Research/ Warburg Gruppe
19.05.2010MeVis kaufenSES Research/ Warburg Gruppe
09.11.2009MeVis kaufenSES Research GmbH
16.09.2009MeVis kaufenSES Research GmbH
08.09.2009MeVis kaufenPerformaxx Research GmbH
DatumRatingAnalyst
12.08.2009MeVis von Seitenlinie beobachtenNebenwerte Journal
18.02.2009MeVis haltenSES Research GmbH
DatumRatingAnalyst
14.11.2007MeVis Medical Solutions nicht zeichnenDer Aktionär

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für MeVis Medical Solutions AG nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen